Narrower-than-Expected Q4 Loss at Repros - Analyst Blog

Repros Therapeutics Inc.'s RPRX fourth quarter 2013 loss of 31 cents per share was narrower than the year-ago loss of 47 cents per share and the Zacks Consensus Estimate of a loss of 38 cents. The narrower loss was due to lower expenses.

The company's revenues for the fourth quarter of 2013 were $4,000 as compared to $2,000 in the year-ago period. All of the revenues came from interest income.

Repros' 2013 loss of $1.33 per share was wider than the year-ago loss of $1.18 per share but narrower than the Zacks Consensus Estimate of a loss of $1.36 per share. Revenues for the year 2013 came in at $9,000 compared with $3,000 in 2012.

Quarter in Details

Both general and administrative (G&A) expenses and research and development (R&D) expenses were down during the reported quarter. While G&A expenses decreased 7.7% to $1.4 million, R&D expenses were down 12% year over year to $5.8 million.

Androxal, the most advanced pipeline candidate at Repros, is being evaluated for the treatment of secondary hypogonadism. In Feb 2014, after a meeting with the U.S. regulatory body regarding Androxal, Repros came to the conclusion that no additional safety studies would be required to support the New Drug Application (NDA) of Androxal. The safety of Androxal will stand on its own merit during NDA review. Repros intends to submit the NDA for the candidate to the U.S. Food and Drug Administration in the fourth quarter of 2014. We expect investor focus to remain on Androxal updates.

Proellex is another candidate in Repros' pipeline. Proellex is being developed for uterine fibroids (vaginal delivery, phase IIb study expected to be initiated soon) and endometriosis (oral delivery, phase II study expected to be completed in the second quarter 2014).

Repros currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks include Alexion Pharmaceuticals, Inc. ALXN, Alkermes ALKS and Gilead Sciences Inc. GILD. All these stocks carry a Zacks Rank #1 (Strong Buy).